ROCHE HLDGS AG (RHHBY)

29.77
0.53 1.75
OTC
Prev Close 30.30
Open 29.77
Day Low/High 29.76 / 29.95
52 Wk Low/High 28.48 / 36.82
Volume 1.24M
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 170.30B
Div & Yield N.A. (N.A)

Latest News

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) as a first-line...

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street futures are edging higher amid a "Super Thursday" of corporate earnings that will culminate with Apple's much-anticipated quarterly update and the first official indication on sales of its flagship iPhone X.

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

-- The VENTANA MMR IHC Panel1 helps differentiate between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer

Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology

Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology

Multi-year partnership to focus on product development and clinical delivery to bring precision medicine to more patients

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

Roche And Accenture Collaborate To Enhance Digital Healthcare For Cancer Patients

Roche And Accenture Collaborate To Enhance Digital Healthcare For Cancer Patients

Data Integration Services Crucial to Decision Support in Oncology

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

Roche And Ignyta Reach Definitive Merger Agreement

Roche And Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan ® (rituximab)...

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated...

Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan (BR) Increased Complete Response Rates Compared To BR Alone In Previously Treated Aggressive Lymphoma

Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine And Rituxan (BR) Increased Complete Response Rates Compared To BR Alone In Previously Treated Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the randomized Phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus...

Genentech's HEMLIBRA (emicizumab-kxwh) Continued To Substantially Reduce Bleeds In People With Hemophilia A With Inhibitors

Genentech's HEMLIBRA (emicizumab-kxwh) Continued To Substantially Reduce Bleeds In People With Hemophilia A With Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the ongoing HEMLIBRA ® (emicizumab-kxwh) clinical development program were presented at the 59th American Society...

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Chemotherapy Reduced The Risk Of Disease Worsening Or Death By 38 Percent For People With A Type Of Advanced Lung Cancer

Phase III IMpower150 Study Showed TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Chemotherapy Reduced The Risk Of Disease Worsening Or Death By 38 Percent For People With A Type Of Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive, pivotal Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus...

Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds In Phase III Study In Hemophilia A

Genentech's HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds In Phase III Study In Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive interim results from the Phase III HAVEN 4 study evaluating HEMLIBRA ® (emicizumab-kxwh) prophylaxis dosed once every four...

FDA Grants Genentech's Avastin Full Approval For Most Aggressive Form Of Brain Cancer

FDA Grants Genentech's Avastin Full Approval For Most Aggressive Form Of Brain Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Launches HyperCap Target Enrichment Portfolio, A Fully Integrated And Streamlined NGS Sample Prep Solution For Research Use

Roche Launches HyperCap Target Enrichment Portfolio, A Fully Integrated And Streamlined NGS Sample Prep Solution For Research Use

- Enables researchers to conveniently obtain all necessary workflow reagents from a single vendor

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche sees success in trials for its cancer and hemophilia drugs

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) And Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (atezolizumab) And Avastin (bevacizumab) Plus Chemotherapy Significantly Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Genentech's HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds In Phase III Study In Hemophilia A

Genentech's HEMLIBRA (emicizumab-kxwh) Significantly Reduced Bleeds In Phase III Study In Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III HAVEN 3 study evaluating HEMLIBRA ® (emicizumab-kxwh) in adults and adolescents (aged 12 years or...